Udenafil

Cat. No.: HY-18253

CAS No.: 268203-93-6

Molecular Formula: $C_{25}H_{36}N_6O_4S$

Molecular Weight: 516.66

Target: Phosphodiesterase (PDE)

Pathway: Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 33 mg/mL (63.87 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.9355 mL	9.6775 mL	19.3551 mL
5 mM	0.3871 mL	1.9355 mL	3.8710 mL
10 mM	0.1936 mL	0.9678 mL	1.9355 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research[1][2].

In Vitro

Udenafil is an oral PDE5 inhibitor. Udenafil significantly increases cAMP and cGMP levels and are more highly distributed in the prostate than plasma[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Zhao, C., et al., Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int, 2011. 107(12): p. 1943-7.

[2]. Paick, J.S., et al., The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5(4): p. 946-53.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA